What pharmacokinetic interactions occur via cytochrome P450 enzyme modulation when sertraline and bupropion (Wellbutrin) are co‑administered?

Pharmacokinetic Interactions Between Sertraline and Bupropion via CYP Enzyme Modulation

Bupropion and sertraline can be safely co-administered with minimal clinically significant pharmacokinetic interactions, though bupropion's inhibition of CYP2D6 may modestly increase sertraline levels, while sertraline's mild CYP2D6 inhibition has negligible effect on bupropion metabolism. 1, 2

Primary Metabolic Pathways

Bupropion Metabolism

• Bupropion is exclusively metabolized by CYP2B6 to its major active metabolite hydroxybupropion, which has approximately 50% of the parent drug's activity 1, 3
• Hydroxybupropion reaches plasma concentrations 4- to 7-fold higher at Cmax and approximately 10-fold greater AUC compared to bupropion at steady state 3
• Two additional active metabolites (threohydrobupropion and erythrohydrobupropion) are formed via non-microsomal pathways, with half-lives of approximately 37 and 33 hours respectively 3
• Bupropion and its metabolites are potent CYP2D6 inhibitors, which is the primary mechanism by which bupropion affects other drugs 1, 4

Sertraline Metabolism

• Sertraline is metabolized primarily through CYP2D6 to desmethylsertraline, which does not significantly inhibit serotonin reuptake 2
• Sertraline is only a mild inhibitor of CYP2D6 and has minimal effects on CYP1A2, CYP3A3/4, CYP2C9, or CYP2C19 2
• Sertraline has a linear pharmacokinetic profile with a half-life of approximately 26 hours 2

Bidirectional Interaction Mechanisms

Bupropion's Effect on Sertraline

• Since bupropion potently inhibits CYP2D6 and sertraline is metabolized by CYP2D6, co-administration may increase sertraline plasma concentrations 1, 2
• The FDA label explicitly lists sertraline among antidepressants whose exposures can be increased when co-administered with bupropion due to CYP2D6 inhibition 1
• Dose reduction of sertraline may be necessary when combined with bupropion, particularly if adverse effects emerge, though sertraline has a relatively wide therapeutic window 1

Sertraline's Effect on Bupropion

• Sertraline has minimal effect on bupropion metabolism because bupropion is metabolized by CYP2B6, not CYP2D6 3, 2
• One preclinical study in mice found that sertraline pretreatment actually resulted in a small increase in bupropion metabolism (27% increase in hydroxybupropion-to-bupropion AUC ratio), suggesting mild CYP2B6 induction rather than inhibition 5
• This finding contradicts in vitro data showing sertraline potently inhibits CYP2B6, highlighting the complexity of predicting clinical interactions from in vitro studies 5
• No dose adjustment of bupropion is typically required when adding sertraline 5, 3

Clinical Management Algorithm

Initiating Combination Therapy

• Start both medications at standard doses as there is no evidence requiring prophylactic dose reduction 6
• For bupropion XL: initiate at 150 mg once daily, may increase to 300 mg once daily after 4 days if tolerated 1
• For sertraline: initiate at 50 mg once daily, may titrate up to 200 mg daily as needed 2

Monitoring Parameters

• Monitor for increased sertraline-related adverse effects including gastrointestinal symptoms (nausea, diarrhea), CNS effects (insomnia, agitation), and sexual dysfunction 2
• Watch for bupropion-related adverse effects including nervousness, insomnia, and tremor, though these are unlikely to be exacerbated by sertraline 4, 3
• Assess for seizure risk factors as bupropion lowers seizure threshold; avoid doses exceeding 450 mg/day of bupropion XL 1

Dose Adjustments

• If sertraline-related adverse effects emerge after adding bupropion, reduce sertraline dose by 25-50% before discontinuing either medication 1
• No routine adjustment of bupropion dosing is needed based on sertraline co-administration 5, 3

Important Clinical Caveats

Protein Binding Considerations

• Sertraline is highly protein bound (>98%) and may theoretically displace other highly protein-bound drugs, though this is rarely clinically significant 2
• This mechanism is independent of CYP-mediated interactions but should be considered with narrow therapeutic index drugs 2

Seizure Threshold

• Both medications can lower seizure threshold, though this is primarily a concern with bupropion 1
• Use extreme caution in patients with seizure disorders, eating disorders, or abrupt benzodiazepine/alcohol withdrawal 1
• The combination does not appear to synergistically increase seizure risk beyond bupropion's baseline risk 6

Clinical Efficacy Evidence

• The combination has demonstrated efficacy in treatment-refractory depression where either agent alone was inadequate 6
• Four case reports showed successful treatment with this combination in patients with chronic depression and multiple prior medication failures, suggesting potential synergism of serotonergic, dopaminergic, and noradrenergic mechanisms 6
• No adverse effects were reported in these combination therapy cases 6

Contraindications and Warnings

• Do not combine bupropion with MAO inhibitors; allow at least 14 days between discontinuing an MAOI and starting bupropion, and vice versa 1
• Minimize or avoid alcohol consumption during bupropion treatment due to rare reports of adverse neuropsychiatric events and reduced alcohol tolerance 1